Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q3 2019 · 10-Q
Revenue$0.00$0.00— vs Q3 2018 Net Income-$8.90M-$8.90MN/M vs Q3 2018 EPS Diluted-$2.67-$2.67N/M vs Q3 2018 Operating Income-$8,946,522N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end